Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine.
about
Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.Identifying currents in the gene pool for bacterial populations using an integrative approach.Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.Meningococcal conjugate vaccines: optimizing global impact.Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.Immunization strategies for the control of serogroup C meningococcal disease in developed countries.Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines.Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135.Routinely vaccinating adolescents against meningococcus: targeting transmission & diseaseBinding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera.Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine.Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease.Optimizing protection against meningococcal disease.Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents.Glycoconjugate vaccines.Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT.Meningococcal vaccines: current issues and future strategies.Evolving meningococcal immunization strategies.Effect of vaccine-elicited antibodies on colonization of Neisseria meningitidis serogroup B and C strains in a human bronchial epithelial cell culture model.Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity.Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine.
P2860
Q30431534-3FB06668-3280-481E-9000-22AE4825B343Q33491540-EEB5AC70-EC30-4E83-9D0D-3C674C4AF26AQ33602953-93B8252E-01D2-4EC6-AD8D-A304D16FE9F7Q34390072-08185300-6C32-4335-898A-383708B6BBB7Q35547767-606975C9-783A-448D-A7C3-48814C7A8F51Q35799561-37F19CA8-F2AC-439A-8560-DFB682BAA686Q36154043-6E7E24FA-FA06-4382-8F66-69CCCBA91055Q36445558-799440C5-0AF5-4777-90B2-B9F05520D4DCQ36530211-C617B062-EF9D-440A-AB91-C7863D440FB5Q36600323-12519788-B0F5-4118-A1A9-669A14EE797CQ36825737-993512B5-EC92-4F17-8B43-A57953F85800Q37075472-162B865B-B971-4D3B-8E6D-32C4EDDC2852Q37130274-1D8DBF29-EE54-494B-B6F5-13653E6C9EEBQ37197065-674864E6-3238-40F0-9AB3-4F74092647D9Q37362174-8931084F-BB9A-4D10-865C-A6948276F4F2Q37678717-DB77C20A-5F97-46DD-8513-26282634F01FQ37713775-00138016-85EC-4F59-AF7D-5D51E94CD142Q38044755-0734E474-7A33-4BC6-9A99-5AAB29B55BDEQ38109830-B0580512-3F9C-49F5-B973-8863E763D0B6Q38120493-99B00E52-67C2-4057-B125-95FF3F2A430FQ38286082-D44EFD20-05A9-41DA-8768-4C844BD3DBA9Q38631739-60079466-DE4B-4022-8FDC-7EC2D3CB5C1FQ42173007-FA1845B4-9791-40A1-BFE0-1D4074ED5677Q45340766-E8A901E1-1B78-4C6B-A2D7-71AEFA7C2F01
P2860
Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Antibody persistence 3 years a ...... ningococcal conjugate vaccine.
@ast
Antibody persistence 3 years a ...... ningococcal conjugate vaccine.
@en
Antibody persistence 3 years a ...... ningococcal conjugate vaccine.
@nl
type
label
Antibody persistence 3 years a ...... ningococcal conjugate vaccine.
@ast
Antibody persistence 3 years a ...... ningococcal conjugate vaccine.
@en
Antibody persistence 3 years a ...... ningococcal conjugate vaccine.
@nl
prefLabel
Antibody persistence 3 years a ...... ningococcal conjugate vaccine.
@ast
Antibody persistence 3 years a ...... ningococcal conjugate vaccine.
@en
Antibody persistence 3 years a ...... ningococcal conjugate vaccine.
@nl
P2093
P921
P356
P1476
Antibody persistence 3 years a ...... eningococcal conjugate vaccine
@en
P2093
Dan M Granoff
Jo Anne Welsch
Josefa V Dela Cruz
Patricia Zuno-Mitchell
P304
P356
10.1086/500512
P407
P50
P577
2006-02-08T00:00:00Z